Edition:
United Kingdom

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

93.75USD
23 May 2018
Change (% chg)

$0.33 (+0.35%)
Prev Close
$93.42
Open
$92.66
Day's High
$95.42
Day's Low
$92.66
Volume
105,917
Avg. Vol
300,652
52-wk High
$95.42
52-wk Low
$41.78

Select another date:

Mon, Apr 30 2018

BRIEF-Neurocrine Biosciences Q1 Loss Per Share $0.47

* NEUROCRINE BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

CORRECTED-UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

CORRECTED-FDA extends review for AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain

April 10 Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis :

BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data

* NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA

BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07

* NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Select another date: